Literature DB >> 21060335

Scientific understanding and clinical management of Dupuytren disease.

Barbara Shih1, Ardeshir Bayat.   

Abstract

Dupuytren disease (DD) is a fibroproliferative disorder of unknown etiology that often results in shortening and thickening of the palmar fascia, leading to permanent and irreversible flexion contracture of the digits. This Review provides a detailed update of the scientific understanding of DD and its clinical management, with perspectives on emerging research and therapy. Established risk factors include genetic predisposition and ethnicity, as well as sex and age. Several environmental risk factors (some considered controversial) include smoking, alcohol intake, trauma, diabetes, epilepsy and use of anticonvulsant drugs, and exposure to vibration. DD has been variously attributed to the presence of oxygen free radicals, trauma to the palmar fascia, or aberrant immune responses with altered antigen presentation, or to interactions between these proposed mechanisms. The presence of immune cells and related phenomena in DD-affected tissue suggests that DD is possibly immune-related. Mechanically, digital contracture is caused by myofibroblasts in the DD palmar fascia; however, the exact origin of this cell type remains unknown. The mainstay of treatment is surgical release or excision of the affected palmodigital tissue, but symptoms often recur. Nonsurgical correction of DD contractures can be achieved by Clostridium histolyticum collagenase injection, although the long-term safety and recurrence rate of this procedure requires further assessment.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 21060335     DOI: 10.1038/nrrheum.2010.180

Source DB:  PubMed          Journal:  Nat Rev Rheumatol        ISSN: 1759-4790            Impact factor:   20.543


  123 in total

Review 1.  Myofibroblasts and mechano-regulation of connective tissue remodelling.

Authors:  James J Tomasek; Giulio Gabbiani; Boris Hinz; Christine Chaponnier; Robert A Brown
Journal:  Nat Rev Mol Cell Biol       Date:  2002-05       Impact factor: 94.444

2.  Mapping of an autosomal dominant gene for Dupuytren's contracture to chromosome 16q in a Swedish family.

Authors:  F Z Hu; A Nystrom; A Ahmed; M Palmquist; R Dopico; I Mossberg; J Gladitz; M Rayner; J C Post; G D Ehrlich; R A Preston
Journal:  Clin Genet       Date:  2005-11       Impact factor: 4.438

3.  Re-visiting Luck's classification: a histological analysis of Dupuytren's disease.

Authors:  W L Lam; J M Rawlins; R O S Karoo; I Naylor; D T Sharpe
Journal:  J Hand Surg Eur Vol       Date:  2010-02-24

4.  The expression of platelet-derived growth-factor gene in Dupuytren contracture.

Authors:  R M Terek; W A Jiranek; M J Goldberg; H J Wolfe; B A Alman
Journal:  J Bone Joint Surg Am       Date:  1995-01       Impact factor: 5.284

5.  Superficial fibromatoses are genetically distinct from deep fibromatoses.

Authors:  E Montgomery; J H Lee; S C Abraham; T T Wu
Journal:  Mod Pathol       Date:  2001-07       Impact factor: 7.842

6.  Epidermal growth factor in Dupuytren's disease.

Authors:  Katarzyna Augoff; Józef Kula; Jerzy Gosk; Roman Rutowski
Journal:  Plast Reconstr Surg       Date:  2005-01       Impact factor: 4.730

7.  Biochemical changes in the collagen of the palmar fascia in patients with Dupuytren's disease.

Authors:  D Brickley-Parsons; M J Glimcher; R J Smith; R Albin; J P Adams
Journal:  J Bone Joint Surg Am       Date:  1981-06       Impact factor: 5.284

8.  Differential gene expression analysis of subcutaneous fat, fascia, and skin overlying a Dupuytren's disease nodule in comparison to control tissue.

Authors:  Barbara Shih; Jason J Brown; Daniel J Armstrong; Tommy Lindau; Ardeshir Bayat
Journal:  Hand (N Y)       Date:  2009-01-29

9.  Basic fibroblast growth factor in Dupuytren's contracture.

Authors:  A M Gonzalez; M Buscaglia; R Fox; A Isacchi; P Sarmientos; J Farris; M Ong; D Martineau; D A Lappi; A Baird
Journal:  Am J Pathol       Date:  1992-09       Impact factor: 4.307

Review 10.  A role for glycosaminoglycans in the development of collagen fibrils.

Authors:  D A Parry; M H Flint; G C Gillard; A S Craig
Journal:  FEBS Lett       Date:  1982-11-22       Impact factor: 4.124

View more
  38 in total

1.  Connective tissue diseases: Unpicking Dupruyten disease etiology-is Wnt the way?

Authors:  Ardeshir Bayat
Journal:  Nat Rev Rheumatol       Date:  2011-11-15       Impact factor: 20.543

Review 2.  The thoracolumbar fascia: anatomy, function and clinical considerations.

Authors:  F H Willard; A Vleeming; M D Schuenke; L Danneels; R Schleip
Journal:  J Anat       Date:  2012-05-27       Impact factor: 2.610

3.  Human Dupuytren's Ex Vivo Culture for the Study of Myofibroblasts and Extracellular Matrix Interactions.

Authors:  Sofia Karkampouna; Peter Kloen; Miryam C Obdeijn; Scott M Riester; Andre J van Wijnen; Marianna Kruithof-de Julio
Journal:  J Vis Exp       Date:  2015-04-18       Impact factor: 1.355

4.  New drugs approved in 2010.

Authors:  Erin Sears; Tegan Steimel
Journal:  Proc (Bayl Univ Med Cent)       Date:  2011-04

5.  Identification of mesenchymal stem cells in perinodular fat and skin in Dupuytren's disease: a potential source of myofibroblasts with implications for pathogenesis and therapy.

Authors:  Syed Amir Iqbal; Christopher Manning; Farhatullah Syed; Venkatesh Kolluru; Mike Hayton; Stewart Watson; Ardeshir Bayat
Journal:  Stem Cells Dev       Date:  2011-07-19       Impact factor: 3.272

6.  The Baron's complaint.

Authors:  Mark A Jobling
Journal:  Investig Genet       Date:  2011-08-18

Review 7.  [Dupuytren's contracture associated with silicone wear reaction in late failure of lunate bone spacer prosthesis].

Authors:  C von Domarus; F T Beil; S Seitz; W Rüther; J Zustin
Journal:  Orthopade       Date:  2013-08       Impact factor: 1.087

8.  Psychometric evaluation of the Disabilities of the Arm, Shoulder and Hand (DASH) with Dupuytren's contracture: validity evidence using Rasch modeling.

Authors:  Nancy J Forget; Christina Jerosch-Herold; Lee Shepstone; Johanne Higgins
Journal:  BMC Musculoskelet Disord       Date:  2014-10-30       Impact factor: 2.362

Review 9.  Optimal functional outcome measures for assessing treatment for Dupuytren's disease: a systematic review and recommendations for future practice.

Authors:  Catherine Ball; Anna L Pratt; Jagdeep Nanchahal
Journal:  BMC Musculoskelet Disord       Date:  2013-04-10       Impact factor: 2.362

10.  Expression of VEGF, its receptors, and HIF-1α in Dupuytren's disease.

Authors:  Lukas A Holzer; Andrej Cör; Gerhard Pfandlsteiner; Gerold Holzer
Journal:  Acta Orthop       Date:  2013-07-03       Impact factor: 3.717

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.